DSMB recommends Stem Cell Therapeutics for phase-IIb acute ischemic stroke trial
Stem Cell Therapeutics Corp has been advised by the Data Safety Monitoring Board (DSMB) that its third and final regularly scheduled safety analysis has been completed and the DSMB has recommended for the phase-IIb acute ischemic stroke trial to continue as per protocol.
[Read the full article here]Related News:
DSMB recommends continuation of Stem Cell Therapeutics’ phase-IIb stroke trial
Stem Cell Therapeutics Corp. Announces Positive Review By Data Safety And Monitoring Board For The Phase IIb Stroke …
Stem Cell Therapeutics Corp. Announces the Third and Final Positive Review by the Data Safety and Monitoring Board for …